Cytokinetics studies the cytoskeleton to get to the heart of the problem. The biopharmaceutical firm's drug development technologies aim to treat disease by modulating muscle function through manipulation of the cytoskeleton (biological infrastructure of cells). Its pipeline includes lead candidate omecamtiv mecarbil, which is designed for the treatment of heart failure based on a cytoskeletal protein in the heart muscle. It is being developed in collaboration with Amgen. Its other lead candidate, tirasemtiv, is in clinical studies for use by patients with ALS. In collaboration with Astellas, Cykokinetics is also studying developing CK-2127107 for the treatment of spinal muscular atrophy (SMA).